Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

XERIS PHARMACEUTICALS, INC.

(XERS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Form 8.3 - The Vanguard Group, Inc. : Xeris Pharmaceuticals, Inc.

06/10/2021 | 09:42am EDT
The Vanguard Group, Inc. ( IRSH) 
Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc. 
10-Jun-2021 / 14:40 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Ap19 
 
FORM 8.3 
 
IRISH TAKEOVER PANEL 
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 
 
DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 
 
1.  KEY INFORMATION 
 
Name of person dealing (Note 1)                                                  The Vanguard Group, Inc. 
Company dealt in                                                                 Xeris Pharmaceuticals, Inc. 
Class of relevant security to which the dealings being disclosed relate (Note 2) USD0.001 Common Stock 
Date of dealing                                                                  08 June 2021 

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

                                             Long            Short 
                                             Numbers   (%)   Numbers (%) 
(1) Relevant securities                      2,631,827 3.97% 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total                                        2,631,827 3.97% 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:                  Long        Short 
                                             Numbers (%) Numbers (%) 
(1) Relevant securities 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total 

Ap20

1. Dealings (Note 4)

(a) Purchases and sales

Purchase/sale Number of relevant securities  Price per unit (Note 5) 
Purchase      14,700                         3.93 USD 

(b) Derivatives transactions (other than options transactions)

Product name,  Nature of transaction Number of relevant securities Price per unit 
e.g. CFD       (Note 6)              (Note 7)                      (Note 5) 
Not Applicable 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, Writing, selling,    Number of securities to               Type, e.g.               Option money paid/ 
              purchasing, varying  which the option relates     Exercise American,         Expiry received per unit 
e.g. call     etc.                 (Note 7)                     price    European etc.     date   (Note 5) 
option 
Not 
Applicable 

(ii) Exercising

Product name,                         Exercise price per unit (Note 5) 
                 Number of securities 
e.g. call option 
Not Applicable 

(e) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction         Price per unit 
                      Details 
(Note 8)                      (if applicable) (Note 5) 
Not Applicable 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating 
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting 
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is 
referenced. If none, this should be stated. 
 
 
 
 

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure                                               10 June 2021 
Contact name                                                     Shawn Acker 
Telephone number                                                 001-610-669-8989 
If a connected EFM, name of offeree/offeror with which connected 
If a connected EFM, state nature of connection (Note 10) ----------------------------------------------------------------------------------------------------------------------- 
Category Code: RET - Xeris Pharmaceuticals, Inc. 
TIDM:          IRSH 
LEI Code:      5493002789CX3L0CJP65 
Sequence No.:  110658 
EQS News ID:   1206755 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1206755&application_name=news 
 

(END) Dow Jones Newswires

June 10, 2021 09:41 ET (13:41 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
XERIS PHARMACEUTICALS, INC. 0.74% 4.11 Delayed Quote.-16.46%
All news about XERIS PHARMACEUTICALS, INC.
06/18FORM 8.3 - THE VANGUARD GROUP, INC.  : Xeris Pharmaceuticals, Inc
DJ
06/16FORM 8.3 - THE VANGUARD GROUP, INC.  : Xeris Pharmaceuticals, Inc
DJ
06/14FORM 8.3 - THE VANGUARD GROUP, INC.  : Xeris Pharmaceuticals, Inc
DJ
06/10FORM 8.3 - THE VANGUARD GROUP, INC.  : Xeris Pharmaceuticals, Inc.
DJ
06/10INVESCO LTD : Form 8.3 - Xeris Pharmaceuticals Inc.
AQ
06/08XERIS PHARMACEUTICALS INC  : Submission of Matters to a Vote of Security Holders..
AQ
06/08FORM 8.3 - THE VANGUARD GROUP, INC.  : Xeris Pharmaceuticals, Inc.
DJ
06/03FORM 8.3 - THE VANGUARD GROUP, INC.  : Xeris Pharmaceuticals, Inc.
DJ
05/31FORM 8.3 - THE VANGUARD GROUP, INC.  : Xeris Pharmaceuticals, Inc
DJ
05/27FORM 8.3 - THE VANGUARD GROUP, INC.  : Xeris Pharmaceuticals, Inc
DJ
More news
Financials (USD)
Sales 2021 47,5 M - -
Net income 2021 -70,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,74x
Yield 2021 -
Capitalization 273 M 273 M -
Capi. / Sales 2021 5,74x
Capi. / Sales 2022 2,81x
Nbr of Employees 209
Free-Float 99,0%
Chart XERIS PHARMACEUTICALS, INC.
Duration : Period :
Xeris Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XERIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,00 $
Last Close Price 4,11 $
Spread / Highest target 192%
Spread / Average Target 143%
Spread / Lowest Target 119%
EPS Revisions
Managers and Directors
NameTitle
Paul R. Edick Chairman & Chief Executive Officer
John Patrick Shannon President & Chief Operating Officer
Barry M. Deutsch Chief Financial Officer
Steven Prestrelski Chief Scientific Officer
Ken Johnson SVP-Clinical Development & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
XERIS PHARMACEUTICALS, INC.-16.46%273
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628